Evaluating the effect of the porous and non-porous colloidal silicon dioxide as a stabilizer on amorphous solid dispersion
Advancement in the discovery of drugs has led to many highly lipophilic compounds with very low water solubility. Amorphous solid dispersion is one of the emerging technologies to increase the solubility of these drugs. The stability of these systems is critical since the high energy system tends to recrystallize, which negates the benefits of these systems. In this paper, we are evaluating the use of colloidal silicon dioxide as a potential stabilizer to stabilize the amorphous solid dispersions. Two types of colloidal silicon dioxide are used: porous colloidal silicon dioxide -Syloid 244 Fp and nonporous fumed silica – Aerosil 200. These silicon dioxides have a high surface area. Two methods of incorporation are used to incorporate silicon dioxide into the solid dispersion. The spray drying method is used to make amorphous solid dispersion. It was found that porous silicon dioxide is better to increase stability as well as increasing dissolution rate and % release of the drug. The addition of silicon dioxide internally to the dispersion increases the dissolution rate, and the addition of silicon dioxide externally increases the stability of the solid dispersion.
Keywords: colloidal silicon dioxide, stabilizer, amorphous solid dispersion, low water solubility
2. Gribbon P, Andreas S. High-throughput drug discovery: What can we expect from HTS? Drug Discovery Today. 2005; 10(1):17-22.
3. Singh A, Worku ZA, Van den Mooter G. Oral formulation strategies to improve solubility of poorly water-soluble drugs. Expert Opinion on Drug Delivery. 2011; 8(10):1361-78.
4. Guzmán HR, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Gardner CR, et al. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci. 2007; 96(10):2686-702.
5. Patil VS, Dziubla TD, Kalika DS. Static and dynamic properties of biodegradable poly (antioxidant β-amino ester) networks based on incorporation of curcumin multiacrylate. Polymer. 2015; 75:88-96.
6. Lakshman JP, Cao Y, Kowalski J, Serajuddin ATM. Application of Melt Extrusion in the Development of a Physically and Chemically Stable High-Energy Amorphous Solid Dispersion of a Poorly Water-Soluble Drug. Molecular Pharmaceutics. 2008; 5(6):994-1002.
7. DiNunzio JC, Brough C, Hughey JR, Miller DA, Williams Iii RO, McGinity JW. Fusion production of solid dispersions containing a heat-sensitive active ingredient by hot melt extrusion and Kinetisol® dispersing. Eur J Pharm Biopharm. 2010; 74(2):340-51.
8. Bouchard A, Jovanović N, Hofland GW, Jiskoot W, Mendes E, Crommelin DJA, et al. Supercritical fluid drying of carbohydrates: Selection of suitable excipients and process conditions. Eur J Pharm Biopharm. 2008; 68(3):781-94.
9. Peltonen L, Hirvonen J. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods. J Pharm Pharmacol. 2010; 62(11):1569-79.
10. Yang W, Tam J, Miller DA, Zhou J, McConville JT, Johnston KP, et al. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Int J Pharm. 2008; 361(1–2):177-88.
11. Patel AD, Agrawal A, Dave RH. Development of polyvinylpyrrolidone-based spray-dried solid dispersions using response surface model and ensemble artificial neural network. J Pharm Sci. 2013; 102(6):1847-58.
12. Chaudhari SP, Gupte A. Mesoporous silica as a carrier for amorphous solid dispersion. arXiv preprint arXiv:170700036. 2017.
13. Patel VI, Dave RH. Evaluation of Colloidal Solid Dispersions: Physiochemical Considerations and In Vitro Release Profile. AAPS PharmSciTech. 2013; 14(2):620-8.
14. Chaudhari SP, Dave RH. Evaluating the Effects of Different Molecular Weights of Polymers in Stabilizing Supersaturated Drug Solutions and Formulations Using Various Methodologies of the Model Drug: Fenofibrate. J Pharm Sci Pharmacol. 2015; 2(3):259-76.
15. Pan X, Julian T, Augsburger L. Quantitative measurement of indomethacin crystallinity in indomethacin-silica gel binary system using differential scanning calorimetry and X-ray powder diffractometry. AAPS PharmSciTech. 2006; 7(1):E72-E8.
16. Pan X, Julian T, Augsburger L. Increasing the Dissolution Rate of a Low-Solubility Drug Through a Crystalline-Amorphous Transition: A Case Study with Indomethicin. Drug Dev Ind Pharm. 2008; 34(2):221-31.
17. Lynne S. Taylor GZ. Spectroscopic Characterization of Interactions Between PVP and Indomethacin in Amorphous Molecular Dispersions. Pharm Res. 1997; 14(12):1691-8.
18. Heinz A, Gordon KC, McGoverin CM, Rades T, Strachan CJ. Understanding the solid-state forms of fenofibrate – A spectroscopic and computational study. Eur J Pharm Biopharm. 2009; 71(1):100-8.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).